Dublin, Feb. 09, 2024 (GLOBE NEWSWIRE) -- The "Prevention and Treatment of Prostate Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
The global market for prostate cancer care reached $35.3 billion in 2022. This market is expected to reach $56.4 billion by the end of 2028, growing at a CAGR of 8.3% from 2023 through 2028.
The ever-evolving landscape of prostate cancer prevention and treatment has reached a pivotal point as per a newly compiled research report that dissects the current market, anticipatory trends, and technology breakthroughs on a global scale. This meticulous study proffers in-depth analysis and revenue forecasts, painting a comprehensive picture of the prostate cancer technologies and treatments from 2023 to 2028.
Deciphering Market Dynamics and Trends
Through detailed research, the report provides an authoritative guide to the global technologies aimed at the prevention and treatment of prostate cancer. Striking a balance between retrospective and prospective insights, the research formulates a historical revenue trajectory for 2020-2022, fused with projected compound annual growth rates (CAGRs) leading up to 2028.
- An in-depth overview of globally prevailing prostate cancer technologies and treatment modalities
- Comprehensive analysis of market trends showcasing revenue data capture for 2020-2022 and future forecasts
- Methodical evaluation of the market size, growth prospects, and segmentation by test, treatment, and drug types as well as geographic regions
Expanding Horizons in Prostate Cancer Detection and Management
The report unravels several prostate cancer types, with an emphasis on prevailing and emerging screening techniques such as PSA testing, DRE, and prostate biopsies, while weighing their respective advantages and limitations. It also delves into the world of poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, spotlighting their therapeutic positioning and regulatory milestones in targeted prostate cancer therapies.
Insights into Regulatory, Patent, and Market Landscape
Innovative therapies and strategies for advanced prostate cancer management, including mCRPC, are comprehensively analyzed within the report. The research emphasizes the importance of regulatory frameworks, reimbursement scenarios, and underscores the significance of collaborative and licencing agreements steering the market.
Discoveries in patent evolution, product pipelines, Environmental, Social, and Governance (ESG) trends, and technologies at the vanguard of prostate cancer prevention and treatment are meticulously scrutinized. Moreover, strategic market maneuvers encompassing mergers, affiliations, and acquisitions are critically examined to offer a panoramic view of the industry's competitive terrain.
Key Market Participants and Competitive Outlook
The report culminates with a sweeping market share analysis of dominant industry players, accompanied by detailed profiles that reflect the current market hierarchy and future potential.
An invaluable resource for stakeholders, investors, and healthcare professionals, this compiled research stands at the forefront, offering an extensive review of prostate cancer prevention and treatments, and maps out the trajectory for the global market's future expansion and innovation.
With its rigorous exploration and detailed forecasts, the report emerges as an essential reference point for understanding the comprehensive global landscape of prostate cancer treatments and technologies, steering market players towards informed decision-making and strategic planning.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 157 |
| Forecast Period | 2023 - 2028 |
| Estimated Market Value (USD) in 2023 | $37.9 Billion |
| Forecasted Market Value (USD) by 2028 | $56.4 Billion |
| Compound Annual Growth Rate | 8.3% |
| Regions Covered | Global |
Key Market Dynamics
Market Drivers
- Increasing Prevalence of Prostate Cancer
- Active Surveillance and Screening
- Personalized Care
- Approvals for Metastatic Castration-Resistant Prostate Cancer
- Collaborations and Licensing Agreements
Market Challenges
- Loss of Exclusivity and Genericization
- Shortage of Care Providers and Other Resources
Companies Profiled
- Abbott
- Accuray
- Astellas Pharma
- Astrazeneca
- Bayer
- Danaher
- Dendreon Pharmaceuticals
- Elekta
- F. Hoffmann-La Roche
- Johnson & Johnson Services
- Pfizer
- Sanofi
- Siemens Healthineers
For more information about this report visit https://www.researchandmarkets.com/r/he0t2m
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
